Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Without Borders
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Practice Current
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Without Borders
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Practice Current
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

September 2020; 7 (5) Clinical/Scientific NotesOpen Access

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis

Jamie Brannigan, Joanne L. Jones, Sybil R. L. Stacpoole
First published June 10, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000799
Jamie Brannigan
From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne L. Jones
From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sybil R. L. Stacpoole
From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
Jamie Brannigan, Joanne L. Jones, Sybil R. L. Stacpoole
Neurol Neuroimmunol Neuroinflamm Sep 2020, 7 (5) e799; DOI: 10.1212/NXI.0000000000000799

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
225

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

A 39-year-old right-handed agricultural service engineer developed rapidly evolving severe relapsing-remitting multiple sclerosis (MS). MRI showed multiple T2 hyperintensities throughout his neuroaxis (figure, A). Several lesions showed restricted diffusion, and 2 enhanced. He received steroids for each relapse, making a full recovery (Expanded Disability Status Score [EDSS] 0).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Evolving imaging features at diagnosis, representation, 3 and 5 weeks later, and after 17 months

(A) MRI of the brain and spinal cord at the point of diagnosis with rapidly evolving relapsing-remitting MS. His initial demyelinating event involved the brainstem and medial longitudinal fasciculus with several areas of involvement in the cerebral cortex. The second event localized to the lower spinal cord, with no evidence of involvement of the cervical spine. (B) MRI of the brain the day after representation, 9 months after the first cycle of alemtuzumab. T2-weighted imaging showed multiple new areas throughout the brain. Diffusion-weighted imaging confirmed appearances suggestive of acute demyelination with multiple areas of restricted diffusion. (C) MRI of the brain and cervical spine 3 weeks after representation. T2-weighted images show extensive demyelination in the brainstem, cerebral cortex, and cervical spine. (D) MRI of the brain at nadir, 5 weeks after representation. T2-weighted imaging illustrates extensive demyelination with areas of T1 signal change. (E) MRI of the brain 17 months later showing remarkable resolution over time.

There was clinical equipoise between induction therapy with alemtuzumab or natalizumab. He was JC virus positive. He chose treatment with alemtuzumab, partly because of the even chance that after 2 cycles, he might not require further treatment, plus the ease of administration, vs the longer-term risks with natalizumab.

Nine months after the first cycle of alemtuzumab, he represented with an encephalopathic picture and progressive focal neurology. He had a headache for 12 days, diplopia for 8 days, and became confused and unsteady on his feet over 5 days. He was apyrexial, looked unwell, was drowsy, and disorientated. Diplopia was present in all directions, and he had mild left upper motor neurone facial weakness and proximal weakness of his lower limbs. Reflexes were difficult to elicit, with upgoing plantars. He deteriorated markedly over the subsequent week, developing ophthalmoplegia, tetraparesis, inability to communicate, and respiratory compromise requiring intubation (EDSS 9.5).

Serum and CSF markers of infection were all negative, including listeria, but his CSF was active with significantly elevated lymphocytes (200 cells/mm3; 90% lymphocytes) and protein (0.85 g/L); glucose was normal. CSF showed unmatched oligoclonal bands. Aquaporin-4 and MOG antibodies were negative.

CSF cytology confirmed reactive lymphocytes (85%). Flow cytometry reported 59% T cells (CD4:CD8 2:1), 35% B cells (kappa:lambda 1.4:1), and 3% NK cells. An additional 13% had a larger morphology and phenotype profile consistent with plasma cells, strongly expressing CD45 and CD38, moderately expressing CD81+, and weakly expressing CD19 and light chains.

Repeat brain MRI revealed numerous new white matter lesions. Most showed restricted diffusion, suggestive of acute demyelination (figure, B), but there was no enhancement (postgadolinium images not shown). EEG showed nonspecific generalized slowing, consistent with generalized cerebral dysfunction/encephalopathy.

His presentation was consistent with encephalitis, with an infective or inflammatory cause. Acyclovir, ceftriaxone, and amoxicillin were administered early, followed by 3,000 mg IV methylprednisolone over 3 days and 10 cycles of alternate day plasma exchange.

There was no clinical response, and repeat MRI brain showed progression (figure, C), still without contrast enhancement (not shown). Severe B cell–mediated demyelination was suspected. Rituximab was commenced and continued 6 monthly, alongside 3 cycles of cyclophosphamide. Subsequent gradual improvement resulted in a remarkable functional recovery (EDSS 3.5 two years later with return to full time work) along with significant remyelination and resolution of T1 black holes (figures, D and E).

Discussion

The first 2 cases of paradoxical disease activation in patients with MS treated with alemtuzumab were reported in 2017.1 The authors proposed that a secondary B cell–driven autoimmune disease targeting the CNS and appearing similar to MS could occur after alemtuzumab therapy due to the observation that B-cell numbers recover far more quickly after alemtuzumab than CD4+ and CD8+ T cells, sometimes overshooting pretreatment levels.1 However, the relative kinetics of B- and T-cell recovery have no effect on the risk of non–CNS-directed autoimmunity. Rather, the risk of developing Graves disease and immune thrombocytopenia after alemtuzumab is associated with poor thymic T-cell recovery and exaggerated CD4+ T-cell homeostatic proliferation.2 CNS-directed alemtuzumab-induced autoimmunity is also unlikely to be due to numerical differences in B- and T-cell counts. Instead, this acute disseminated encephalomyelitis-like illness after alemtuzumab is more likely to result from the complex interplay of multiple reconstituting immune cell subsets.

Eleven of the other 17 reported cases of disease activation after alemtuzumab occurred in those switching therapies directly from fingolimod,1,3,4 suggesting confounding of pathologic mechanisms. Following treatment with fingolimod, many lymphocytes remain hidden from the intravascular therapeutic effects of alemtuzumab due to selective lymphoid sequestration. Later egression could initiate rebound activity, which also occurs if fingolimod treatment is stopped without substituting a different therapy.3 This disease activity would be due to a failure of alemtuzumab to bind to CD52+ lymphocytes, not the repopulation kinetics of B and T cells after treatment.

One question on encountering paradoxical disease activation after alemtuzumab is whether to proceed to the second treatment cycle or switch to rituximab (or an alternative anti-CD20 B-cell therapy such as ocrelizumab). Five patients in the literature received rituximab; 6 including ours. All have responded well. Willis' case series of disease activity 4–5 months post-alemtuzumab in patients switched from fingolimod responded well to the second cycle of alemtuzumab, as might be expected from the mechanisms discussed above.

We hope that the remarkable recovery of our patient, despite extensive brainstem involvement, will provide clinicians with the confidence to treat in such severe situations.

Study funding

No targeted funding was provided. J.L. Jones is supported by the Wellcome Trust (RG49413).

Disclosure

J. Brannigan and S.R.L. Stacpoole report no disclosures relevant to the manuscript. J.L. Jones has received honoraria from Sanofi-Genzyme. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table1

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the Wellcome Trust.

  • Received January 6, 2020.
  • Accepted in final form April 22, 2020.
  • Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

  1. 1.↵
    1. Haghikia A,
    2. Dendrou CA,
    3. Schneider R, et al
    . Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol 2017;16:104–106.
    OpenUrl
  2. 2.↵
    1. Jones JL,
    2. Thompson SAJ,
    3. Loh P, et al
    . Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A 2013;110:20200–20205.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Willis M,
    2. Pearson O,
    3. Illes Z, et al
    . An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2017;4:e320. doi:10.1212/NXI.0000000000000320.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Wehrum T,
    2. Beume LA,
    3. Stich O, et al
    . Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology 2018;90:e1–e5.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Discussion
    • Study funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures

Related Articles

  • No related articles found.

Topics Discussed

  • Multiple sclerosis
  • Autoimmune diseases
  • Encephalitis
  • Acute disseminated encephalomyelitis

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology - Neuroimmunology Neuroinflammation: 8 (3)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise